The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2024 | The future of immunotherapies in treating GI cancer
Kohei Shitara, MD, National Cancer Center Hospital East, Kashiwa, Japan, discusses the future of claudin-18.2 targeted CAR-T cell therapies in patients with gastrointestinal (GI) cancer, which show promising overall survival (OS) and progression-free survival (PFS) rates. Tumor-infiltrating lymphocyte (TIL) therapies have also demonstrated effectiveness in treating solid tumors, including GI cancers. However, there is an emphasis on carrying out further research on these therapies.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria – Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Janssen; Lilly; Ono Pharmaceutical
Consulting or Advisory Role – ALX Oncology; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Guardant Health; MSD; Novartis; Ono Pharmaceutical; Takeda; Zymeworks
Research Funding – Amgen (Inst); Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); MSD (Inst); Ono Pharmaceutical (Inst); PRA Health Sciences (Inst); Taiho Pharmaceutical (Inst)
